全文获取类型
收费全文 | 205031篇 |
免费 | 12502篇 |
国内免费 | 526篇 |
专业分类
耳鼻咽喉 | 2558篇 |
儿科学 | 6703篇 |
妇产科学 | 4589篇 |
基础医学 | 27981篇 |
口腔科学 | 8039篇 |
临床医学 | 18278篇 |
内科学 | 44249篇 |
皮肤病学 | 4904篇 |
神经病学 | 17597篇 |
特种医学 | 5944篇 |
外国民族医学 | 26篇 |
外科学 | 24254篇 |
综合类 | 1776篇 |
现状与发展 | 1篇 |
一般理论 | 116篇 |
预防医学 | 21952篇 |
眼科学 | 3606篇 |
药学 | 12393篇 |
中国医学 | 747篇 |
肿瘤学 | 12346篇 |
出版年
2023年 | 993篇 |
2022年 | 1121篇 |
2021年 | 4343篇 |
2020年 | 2866篇 |
2019年 | 4195篇 |
2018年 | 5692篇 |
2017年 | 4219篇 |
2016年 | 4018篇 |
2015年 | 4759篇 |
2014年 | 6566篇 |
2013年 | 8593篇 |
2012年 | 13259篇 |
2011年 | 13919篇 |
2010年 | 7119篇 |
2009年 | 6345篇 |
2008年 | 11135篇 |
2007年 | 11755篇 |
2006年 | 11098篇 |
2005年 | 11193篇 |
2004年 | 10621篇 |
2003年 | 9780篇 |
2002年 | 7703篇 |
2001年 | 5217篇 |
2000年 | 5150篇 |
1999年 | 4687篇 |
1998年 | 1959篇 |
1997年 | 1656篇 |
1996年 | 1610篇 |
1995年 | 1376篇 |
1994年 | 1345篇 |
1993年 | 1233篇 |
1992年 | 2855篇 |
1991年 | 2738篇 |
1990年 | 2491篇 |
1989年 | 2489篇 |
1988年 | 2236篇 |
1987年 | 2073篇 |
1986年 | 1932篇 |
1985年 | 1861篇 |
1984年 | 1413篇 |
1983年 | 1172篇 |
1982年 | 760篇 |
1981年 | 675篇 |
1980年 | 653篇 |
1979年 | 1024篇 |
1978年 | 686篇 |
1977年 | 549篇 |
1975年 | 595篇 |
1974年 | 607篇 |
1973年 | 592篇 |
排序方式: 共有10000条查询结果,搜索用时 250 毫秒
1.
2.
3.
4.
Emeline Colomba Patricia Pautier Fanny Pommeret Alexandra Leary 《Expert review of anticancer therapy》2019,19(6):437-446
Introduction: The landscape of poly (ADP-ribose) polymerase (PARP) inhibition in ovarian cancer is rapidly evolving and becoming increasingly complex. Ovarian cancer is leading therapeutic innovation by providing the proof of concept for DNA repair as a target. Three different PARP inhibitors have now received approvals in the US and Europe in different indications. Subtle but crucial differences can be found among the licensed indications for each PARP inhibitor in terms of histology, type of BRCA mutation (germline and/or somatic), number of prior lines of chemotherapy and whether the indication is in the treatment or maintenance settings.
Areas covered: We review the latest clinical data regarding the PARP inhibitor rucaparib in ovarian cancer, provide an update on the evolving landscape of PARP inhibition in ovarian cancer, and summarize avenues of ongoing and future research.
Expert opinion: All eligible patients should be offered a PARP inhibitor. SOLO1 trial results demonstrated an unprecedented benefit maintenance with PARP inhibitors in first line. Results from trials evaluating PARP inhibitors as maintenance in first line regardless of BRCA status and from trials evaluating combinatorial strategies are eagerly awaited. 相似文献
5.
Rupa Narayan MD Traci M. Blonquist MS Ashkan Emadi MD PhD Robert P. Hasserjian MD Meghan Burke BS Christopher Lescinskas BS Donna S. Neuberg ScD Andrew M. Brunner MD Gabriela Hobbs MD Hanno Hock MD PhD Steven L. McAfee MD Yi-Bin Chen MD Eyal Attar MD Timothy A. Graubert MD Christina Bertoli MSN Jenna A. Moran MSN Meghan K. Bergeron MSN Julia E. Foster MSN Aura Y. Ramos BSN Tina T. Som BSN Megan K. Vartanian BSN RN Jennifer L. Story LPN Kristin McGregor MS Molly Macrae BS Tanya Behnan BS Margaret C. Wey PhD Jessica Rae BSN Frederic I. Preffer PhD Patricia Lesho BA Vu H. Duong MD Mason L. Mann BA Karen K. Ballen MD Christine Connolly BS Philip C. Amrein MD Amir T. Fathi MD 《Cancer》2020,126(6):1264-1273
6.
7.
Sarina A. Piha-Paul Do-Youn Oh Makoto Ueno David Malka Hyun Cheol Chung Adnan Nagrial Robin K. Kelley Willeke Ros Antoine Italiano Kazuhiko Nakagawa Hope S. Rugo Filippo de Braud Andrea Iolanda Varga Aaron Hansen Hui Wang Suba Krishnan Kevin G. Norwood Toshihiko Doi 《International journal of cancer. Journal international du cancer》2020,147(8):2190-2198
We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity. 相似文献
8.
Selwyn Arlington Headley Nayara Emily Viana Mariana de Mello Zanim Michelazzo Ana Aparecida Correa Xavier Cícero Júlio Silva Costa Felipe Hideki Ogo de Pinho Marcelo Diniz dos Santos 《Transboundary and Emerging Diseases》2020,67(Z2):49-59
Neorickettsia helminthoeca (NH), the agent of salmon poisoning disease or canine neorickettiosis (CN), is a bacterial endosymbiont of the nematode Nanophyetus salmincola, and infections are spreading among specific fish‐eating mammalians. This article describes the pathologic and immunohistochemical findings associated with spontaneous NH‐induced infections in dogs from Southern Brazil. The principal pathologic findings were hypertrophy of Peyer patches and lymphadenopathy with lymphocytic proliferation, chronic interstitial pneumonia, and chronic enteritis associated with positive intralesional immunoreactivity to antigens of NH within macrophages and histiocytes. Positive immunoreactivity against canine parvovirus‐2 (CPV‐2) or/and canine distemper virus was not detected in the evaluated intestinal segments or in the samples from the cerebellum and lungs, respectively, from the dogs evaluated. These findings demonstrated that NH was involved in the enteric, pulmonary, and lymphoid lesions herein described, and provide additional information to confirm the occurrence of this bacterial endosymbiont within this geographical location. It is proposed that chronic pneumonia should be considered as a pathologic manifestation of NH‐induced infections. Additionally, our results show that the occurrences of CN seem to be underdiagnosed in Southern Brazil due to the confusion with the incidence of CPV‐2. 相似文献
9.
10.